Octreotide · source year
9 selected, source-linked Octreotide records carrying a 2017 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
9 selected records.
2 represented types.
9 distinct public records.
Cited chronology
Regulatory
The Federal Register published notice 2017-25920, attributed to FDA and its parent HHS department, on 2017-12-01. Its official title is “Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03061604 at 2026-07-30T21:22:00.250Z. Its registry update date was 2017-11-14, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02474914 at 2026-07-30T21:23:14.756Z. Its registry update date was 2017-08-22, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00600886 at 2026-07-30T21:23:14.761Z. Its registry update date was 2017-07-02, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2017-12908, attributed to FDA and its parent HHS department, on 2017-06-21. Its official title is “Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00182754 at 2026-07-30T21:24:24.234Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00332969 at 2026-07-30T21:25:36.783Z. Its registry update date was 2017-03-31, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00171886 at 2026-07-30T21:25:36.764Z. Its registry update date was 2017-02-24, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00223691 at 2026-07-30T21:25:36.812Z. Its registry update date was 2017-01-18, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗